PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 September; 7(3): E1–E11.
Published online 2006 July 7. doi:  10.1208/pt070356
PMCID: PMC2750498

Osmotic flow through asymmetric membrane: A means for controlled delivery of drugs with varying solubility

Abstract

A nondisintegrating, controlled release, asymmetric membrane capsular system of flurbiprofen was developed and evaluated for controlled release of the drug to overcome some of its side effects. Asymmetric membrane capsules were prepared using fabricated glass mold pins by phase inversion process. The effect of different formulation variables was studied based on 23 factorial design; namely, level of osmogen, membrane thickness, and level of pore former. Effects of polymer diffusibility and varying osmotic pressure on drug release were also studied. Membrane characterization by scanning electron microscopy showed an outer dense region with less pores and an inner porous region for the prepared asymmetric membrane. Differential scanning calorimetry studies showed no incompatibility between the drug and the excipients used in the study. In vitro release studies for all the prepared formulations were done (n=6). Statistical test (Dunnett multiple comparison test) was applied for in vitro drug release atP>.05. The best formulation closely corresponded to the extra design checkpoint formulation by a similarity (f2) value of 92.94. The drug release was independent of pH but dependent on the osmotic pressure of the dissolution medium. The release kinetics followed the Higuchi model and the mechanism of release was Fickian diffusion.

Keywords: asymmetric membrane, factorial design, extra design, polymer diffusibility

Full Text

The Full Text of this article is available as a PDF (643K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release. 1995;35:1–21. doi: 10.1016/0168-3659(95)00013-X. [Cross Ref]
2. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987–1991. doi: 10.1002/jps.2600641218. [PubMed] [Cross Ref]
3. Theeuwes F, Saunders RJ, Mefford WS, inventors. Process for forming outlet passageways in pills using a laser. US parent 4 088 864. May 9, 1978.
4. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric membrane tablet coatings for osmotic drug delivery. J Control Release. 1995;35:127–136. doi: 10.1016/0168-3659(95)00028-7. [Cross Ref]
5. Thombre AG, Cardinal JR, DeNoto AR, Gibbes DC. Asymmetric membrane capsules for osmotic drug delivery. II. In vitro and in vivo drug release performance. J Control Release. 1999;57:65–73. doi: 10.1016/S0168-3659(98)00101-1. [PubMed] [Cross Ref]
6. Thombre AG, Cardinal JR, DeNoto AR, Herbig SM, Smith KL. Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process. J Control Release. 1999;57:55–64. doi: 10.1016/S0168-3659(98)00100-X. [PubMed] [Cross Ref]
7. Lin YK, Ho HO. Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice. J Control Release. 2003;89:57–69. doi: 10.1016/S0168-3659(03)00091-9. [PubMed] [Cross Ref]
8. Marsh CC, Schuna AA, Sundstorm WR. A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s. Pharmacotherapy. 1986;6:10–25. [PubMed]
9. Gilman AG, Rall TW, Taylor P. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. New York, NY: Pergamon Press; 1990.
10. British National Formulary 45. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2003.
11. Thaller VT, Kulshrestha MK, Bell K. The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation. Eye. 2000;14:642–645. [PubMed]
12. Chandran C, Roy A, Saha RN. Flurbiprofen: a review. Indian J Pharm Educ. 2005;39:22–26.
13. McClelland GA, Sutton SC, Engle K, Zentner GM. Solubility modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride. Pharm Res. 1991;8:88–92. doi: 10.1023/A:1015890525495. [PubMed] [Cross Ref]
14. Zentner GM, McClelland GA, Sutton SC. Controlled porosity solubility and resin modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Control Release. 1991;16:237–244. doi: 10.1016/0168-3659(91)90047-H. [Cross Ref]
15. Martin A. Physical Pharmacy. New Delhi, India: B. I. Waverly Pvt Ltd; 1999.
16. Rawlins EA. Bentley’s Textbook of Pharmaceutics. London, UK: Bailliere Tindall; 2004.
17. Bennett PN, Brown MJ. Clinical Pharmacology. London, UK: Churchill Livingstone; 2004.
18. Chien YW. Novel Drug Delivery Systems. New York NY: Marcel Dekker Inc; 1992.
19. Najib N, Suleiman M. The kinetics of drug release from ethyl cellulose solid dispersions. Drug Dev Ind Pharm. 1985;11:2169–2181. doi: 10.3109/03639048509087779. [Cross Ref]
20. Desai SJ, Singh P, Simonelli AP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving polyethylene plastic matrix. J Pharm Sci. 1966;55:1230–1234. doi: 10.1002/jps.2600551113. [PubMed] [Cross Ref]
21. Higuchi T. Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149. doi: 10.1002/jps.2600521210. [PubMed] [Cross Ref]
22. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I—theoretical consideration. Ind Eng Chem. 1931;23:923–931. doi: 10.1021/ie50260a018. [Cross Ref]
23. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35. doi: 10.1016/0378-5173(83)90064-9. [Cross Ref]
24. Avdeef A. pH-metric solubility 1: solubility pH profiles from bjerrum plots. Gibbs buffer and pKa in solid state. Pharmacy and Pharmacology Communications. 1998;4:165–178.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists